Volume 3.29 | Aug 3

Prostate Cell News 3.29 August 3, 2012
     In this issue: Publications | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter

Differential Role of Sloan-Kettering Institute (Ski) Protein in Nodal and Transforming Growth Factor-Beta (TGF-β) Induced Smad Signaling in Prostate Cancer Cells
Researchers determined the expression and differential role of Ski, a co-repressor of Smad2/3, in Nodal and TGF-β signaling in prostate cancer cells. [Carcinogenesis] Abstract

Ready Sep Go: Request a Free Cell Isolation Wallchart

PUBLICATIONS (Ranked by impact factor of the journal)


XMRV Induces Cell Migration, Cytokine Expression and Tumor Angiogenesis: Are 22Rv1 Cells a Suitable Prostate Cancer Model?
Scientists demonstrated that 22Rv1 cells with reduced retroviral transcription show reduced tumor angiogenesis and increased necrosis of the primary tumor derived from xenografted cells in scid mice when compared to the parental cell line. [PLoS One] Full Article

In Vivo Biomarker Expression Patterns Are Preserved in 3D Cultures of Prostate Cancer
Investigators report that prostate cancer cell-lines DU145, PC3, LNCaP and RWPE-1 grown in 3D matrices in contrast to conventional 2D monolayers, display distinct differences in cell morphology, proliferation and expression of important biomarker proteins associated with cancer progression. [Exp Cell Res] Abstract

Human Papillomavirus and Epstein Barr Virus in Prostate Cancer: Koilocytes Indicate Potential Oncogenic Influences of Human Papillomavirus in Prostate Cancer
Scientists indentified both human papillomaviruses type 18 and Epstein Barr virus gene sequences in a high and approximately equal proportion of normal, benign, and prostate cancer specimens. [Prostate]
Abstract | Press Release

Evaluation of a Technetium-99m Labeled Bombesin Homodimer for GRPR Imaging in Prostate Cancer
Researchers developed a new bombesin homodimer based on an ε-aminocaproic acid-bombesin(7–14) fragment, which has been studied for targeting the gastrin-releasing peptide receptor (GRPR) in prostate cancer. [Amino Acids] Abstract

Demethoxycurcumin Modulates Prostate Cancer Cells Proliferation via AMPK-Induced Down-Regulation of Heat Shock Protein 70 and Epidermal Growth Factor Receptor
Investigators examined the effects of three curcuminoid analogs on prostate cancer cells. Results revealed that demethoxycurcumin demonstrated the most efficient cytotoxic effects on prostate cancer PC3 cells. [J Agric Food Chem] Abstract

Tumor Suppressive MicroRNAs (miR-222 and miR-31) Regulate Molecular Pathways Based on MicroRNA Expression Signature in Prostate Cancer
Researchers focused on four downregulated microRNAs (miR-187, miR-205, miR-222 and miR-31) to investigate their functional significance in prostate cancer cells. [J Hum Genet] Abstract

Identification of Ryanodine Receptor Isoforms in Prostate DU-145, LNCaP, and PWR-1E Cells
Scientists identified the ryanodine receptor isoforms expressed in widely used prostate cancer cell lines, DU-145 and LNCaP, and the non-tumorigenic prostate cell line, PWR-1E. [Biochem Biophys Res Commun] Abstract

Expression of Melanocortin Receptors in Human Prostate Cancer Cell Lines: MC2R Activation by Adrenocorticotropic Hormone Increases Prostate Cancer Cell Proliferation
Investigators showed that melanocortin receptors (MCR) (1-5) mRNAs are expressed in androgen-dependent LNCaP and androgen-independent PC3 and DU-145 human prostate cancer cell lines. [Int J Oncol] Abstract

Glycosylation Potential of Human Prostate Cancer Cell Lines
Researchers investigated enzymatic activities and gene expression levels of key glycosyl- and sulfotransferases responsible for the assembly of O- and N-glycans in several prostatic cells. [Glycoconj J] Abstract


Long Term Results of a Prospective Dose Escalation Phase-II Trial: Interstitial Pulsed-Dose-Rate Brachytherapy as Boost for Intermediate- and High-Risk Prostate Cancer
Scientists report on a seven year single institution experience with pulsed dose rate brachytherapy dose escalation study in patients with intermediate and high risk prostate cancer. [Radiother Oncol] Abstract

Phase II Study of First-Line Sagopilone plus Prednisone in Patients with Castration-Resistant Prostate Cancer: A Phase II Study of the Department of Defense Prostate Cancer Clinical Trials Consortium
Researchers investigated the activity and safety of sagopilone in patients with metastatic castration-resistant prostate cancer. [Br J Cancer] Abstract

Do Your Colleagues Know What They Are Missing? Share This Newsletter Now.

StemSpan™ ACF, the First Plasma Component-Free Hematopoietic Expansion Media
STEMCELL Technologies Inc. announced the launch of StemSpan™ ACF, a new animal component- free (ACF) and chemically-defined hematopoietic stem cell expansion medium, which contains no animal and human plasma-derived components. [STEMCELL Technologies Inc.] Press Release

Genspera Cleared to Initiate Phase II G-202 Trial In Prostate Cancer
GenSpera, Inc. announced that the U.S. Food and Drug Administration has cleared for initiation a Phase II human clinical trial of G-202 in the treatment of prostate cancer patients who have failed prior hormonal therapy. [GenSpera, Inc.] Press Release

Medifocus Announces Acquisition of Prolieve Device for Treatment of Benign Prostatic Hyperplasia from Boston Scientific

Medifocus Inc. announced an agreement with Boston Scientific Corporation for the purchase of all of the assets of its Prolieve® business, which sells devices for the treatment of benign prostatic hyperplasia. [Medifocus Inc.] Press Release

Investing in the Future of Prostate Cancer Research
Prostate Cancer Canada is proud to debut its new Movember Team Grants program, awarding up to $6 million in funding to collaborative and innovative research teams in the field of prostate cancer. [Prostate Cancer Canada ]
Press Release


National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW 2012 Science of Global Prostate Cancer Disparities Conference
November 1-4, 2012
Nassau, The Bahamas

Visit our events page to see a complete list of events in the prostate cell community.


Quality Control Operations Coordinator (STEMCELL Technologies, Inc.)

Research Associate – Chemistry (STEMCELL Technologies, Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies, Inc.)

Research Technologist – Research and Development (STEMCELL Technologies, Inc.)

Research Technologist – Contract Assay Services (STEMCELL Technologies, Inc.)

Research Technologist – Media Development (STEMCELL Technologies, Inc.)

Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.)

Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies, Inc.)

Scientist – Mesenchymal Cell Research (STEMCELL Technologies, Inc.)

Scientist – hPSC Bioengineering (STEMCELL Technologies, Inc.)

Postdoctoral Position – Prostate Cancer (BC Cancer Agency)

Postdoctoral Position – Endocrinology of Prostate Cancer (Baylor College of Medicine)

Postdoctoral Position – Prostate Cancer Research (University of Texas Southwestern Medical Center)

Postdoctoral Position – Systems Biology in Prostate Cancer (Karolinska Institutet)

Recruit Top Talent: Reach more than 55,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives | Events | Contact Us